Omid Veiseh
From Wikipedia, the free encyclopedia
PhD, Materials Science and Engineering and Nanotechnology, 2009, University of Washington, PostDoc, MIT
Omid Veiseh | |
|---|---|
| Academic background | |
| Education | BS, Western Washington University PhD, Materials Science and Engineering and Nanotechnology, 2009, University of Washington, PostDoc, MIT |
| Academic work | |
| Institutions | Rice University |
| Website | veisehlab |
Omid Veiseh is an American biomaterials researcher and entrepreneur. As a postdoctorate candidate at MIT, he co-founded Siglion Therapeutics, a biotechnology company which would commercialize the discoveries he and his co-founders developed. In 2016, Veiseh was offered a faculty position in the Department of Bioengineering at Rice University.
Veiseh earned his Bachelor of Science degree from Western Washington University and his PhD from the University of Washington.[1] Upon completing his PhD, Veiseh completed his post-doctoral research at MIT's Koch Institute for Integrative Cancer Research where he co-developed a way to reduce immune-system rejection using biomedical devices.[2] While at MIT, he co-founded Sigilon Therapeutics, a biotechnology company which would commercialize the discoveries he and his co-founders developed.[3]